In this article, we will discuss the 10 Fastest Growing Penny Stocks to Buy Now.
Have the markets peaked? That’s the big question following a blockbuster year in which equity markets raced to record highs. Nevertheless, concerns about valuations and a profit-taking spree are already spelling doom for one of the longest bull runs in recent years. With Bitcoin plunging below the $100,000-a-coin level, it’s becoming increasingly clear that demand for risk-taking is waning in the markets.
CFRA’s chief investment strategist, Sam Stovall, has warned of a potential pullback of up to 9%. Goldman Sachs President John Waldron believes the market is primed for possible declines, citing technical factors that point to downside action. The sentiments come amid concerns about whether companies will generate returns following billions of dollars of investments in artificial intelligence.
“It strikes me the market could pull back further from here,” Waldron said in an interview on the sidelines of the Bloomberg New Economy Forum in Singapore on Wednesday. “I do think the technicals are kind of more biased for more protection, and more downside.”
Amid growing concerns of a potential market correction, small-cap and penny stocks trading at highly discounted valuations could be spared the wrath. The US Federal Reserve, embarking on an interest rate-cutting spree, is expected to spur economic growth, presenting a macroeconomic environment that benefits companies with smaller capitalizations.
Over the years, small-cap companies have outperformed large-cap companies during central bank easing cycles.
“Further, small-cap returns in these instances have been much better than for large-cap stocks. The average return for the [Russell 2000] 12 months following these post-pause rate cuts is 35% vs. 23% for the SPX ,” Canaccord Genuity analyst Michael Graham wrote
Tom Lee, head of research at Fundstrat Global Advisors, has already reiterated that a dovish US Federal Reserve often translates into good times for smaller companies in terms of performance.
“I think it means we have a dovish Fed again,” Lee said. “That’s kind of a green light for small caps.”
With that in mind, let’s take a look at some of the fastest-growing penny stocks to buy now.
Our Methodology
To compile the list of fastest-growing penny stocks to buy now, we used Finviz Screener and other online sources to identify stocks trading for less than $5 a share. We further trimmed our list by focusing on companies that have generated more than 100% sales growth over the past year and 50% growth over the past three years. We also focused on stocks that boast an upside potential of more than 30% as of November 19 and are popular among elite hedge funds in Q2 2025. Finally, we ranked the stocks in ascending order based on their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Fastest Growing Penny Stocks to Buy Now
10. DeFi Technologies Inc. (NASDAQ:DEFT)
3-Year Sales Growth: 1181.92%
Sales Growth Year over Year: 138.94%
Stock Upside Potential: 78.21%
Number of Hedge Fund Holders: 9
DeFi Technologies Inc. (NASDAQ:DEFT) is one of the fastest-growing penny stocks to buy now. On November 17, Maxim Group analyst Matthew Galinko reiterated a Buy rating on DeFi Technologies Inc. (NASDAQ:DEFT), impressed by the increase in assets under management and the expansion of Exchange Traded Products.
The analyst expects the company to enjoy robust growth with the launch of new Exchange Traded Products strategies, followed by expansion into new geographies. The company is also well-positioned to benefit from expanding liquidity and advisory services. A strong financial position, coupled with significant cash reserves and cryptocurrency holdings also affirms its long-term prospects.
The remarks come on the heels of DeFi Technologies delivering mixed third-quarter results on November 14, in which revenues dropped to $22.5 million from $28.1 million in the same quarter last year. The decline was due to lower revenues from realized and net changes in unrealized gains on digital assets. Operating income also fell to $9 million from $14.4 million, driven by lower revenues.
“With average AUM exceeding $900 million per month in the third quarter, the highest quarterly average in history, and net inflows every month year-to-date, we continue to demonstrate the power of our integrated asset management and trading ecosystem,” said CEO, Olivier Roussy Newton.
DeFi Technologies Inc. (NASDAQ:DEFT) is a financial technology company that bridges traditional finance with decentralized finance (DeFi) by offering regulated products and services. It creates and issues exchange-traded products (ETPs) that provide indirect exposure to digital assets and DeFi protocols.
9. Ur-Energy Inc. (NYSE:URG)
3-Year Sales Growth: 1181.92%
Sales Growth Year over Year: 138.94%
Stock Upside Potential: 80.21%
Number of Hedge Fund Holders: 22
Ur-Energy Inc. (NYSE:URG) is one of the fastest-growing penny stocks to buy now. On November 6, Maxim Group analyst Tate Sullivan reiterated a Buy rating on Ur-Energy Inc. (NYSE:URG). According to the analyst, the company is well-positioned to benefit from growing uranium demand from US customers.
The company has already secured significant off-take agreements with US commercial nuclear power plants, underscoring its long-term prospects. It has also reiterated its 2025 revenue guidance, which expects to sell 440,000 pounds of U3O8 at an average price of $61.77 per pound. It expects to realize revenues of $27.2 million.
Ur-Energy is also on course to start production at its second uranium mining project in Wyoming as it looks to capitalize on growing uranium demand. It’s also ramping up production at Lost Creek, which produced 93,525 pounds of U308, dried and packaged, in the third quarter.
On November 4, analysts at H.C. Wainwright cut their price target of the stock to $2.60 from $2.70 but reiterated a Buy rating. According to the research firm, the use of purchased inventories should help protect and maximize the value of low-cost products in the long term.
Ur-Energy Inc. (NYSE:URG) is a U.S.-based uranium mining company that acquires, explores, develops, and operates uranium properties in the United States. It specializes in the environmentally sensitive in-situ recovery (ISR) method of uranium extraction, which leaves the rock in place. Its flagship project is the Lost Creek project in Wyoming, and it is also developing the Shirley Basin project.
8. PowerFleet, Inc. (NASDAQ:AIOT)
3-Year Sales Growth: 38.68%
Sales Growth Year over Year: 92.56%
Stock Upside Potential: 134.90%
Number of Hedge Fund Holders: 23
PowerFleet Inc. (NASDAQ:AIOT) is one of the fastest-growing penny stocks to buy now. On November 11, William Blair reiterated an Outperform rating, impressed by PowerFleet Inc. (NASDAQ:AIOT)’s second-quarter 2026 results, characterized by record revenue and strong performance across key metrics.
The company achieved double-digit year-over-year organic annual recurring revenue growth driven by strong global traction across direct and indirect channels. Total revenue increased 45% to a record high of $111.7 million, driven by expanding adoption of the company’s AIoT platform. Gross profit increased 51% year-over-year to $62.6 million.
William Blair has touted the company on achieving 12% organic services growth amid broad-based business strength and accelerating pipeline momentum.
“Strong product revenue with a sequential revenue improvement of 27%, as well as solid sequential margin expansion, highlights continued momentum and resilience amid evolving macroeconomic conditions,” said Steve Towe, Chief Executive Officer.
However, the company delivered a wider-than-expected net loss attributable to stockholders of $4.3 million, or $0.03 a share, compared to a net loss of $1.9 million, or $0.02 a share, for the same quarter last year. The wider-than-expected net loss was due to higher interest expenses and non-cash amortization.
PowerFleet, Inc. (NASDAQ:AIOT) is a global AIoT (Artificial Intelligence of Things) company that provides software-as-a-service (SaaS) solutions to help organizations manage, monitor, and optimize assets like connected vehicles and warehouse equipment.
7. Atlantic International Corp. (NASDAQ:ATLN)
3-Year Sales Growth: 1182.15%%
Sales Growth Year over Year: 109.65%
Stock Upside Potential: 137.15%
Number of Hedge Fund Holders: N/A
Atlantic International Corp (NASDAQ:ATLN) is one of the fastest-growing penny stocks to buy now. On November 17, Atlantic International Corp (NASDAQ: ATLN) reported continued momentum in its Q3 2025 results, highlighting a strengthened financial trajectory and improved year-to-date performance. The company credited cost-cutting and efficiency measures for sharply reducing its net loss.
Net loss for the first nine months of the year narrowed to $32.2 million, or $0.58 a share, compared to a net loss of $66.8 million, or $2.04 a share, for the same period last year. Adjusted EBITDA also improved to negative $0.7 million from negative $2.7 million, underlining the impact of cost and efficiency actions.
The narrowing of net loss comes on revenue for the first nine months of the year, reaching record highs of $315.8 million, driven by a record quarter of $110.1 million. Management expects significant improvement heading into year-end and into next year, driven by additional efficiency initiatives.
“We are encouraged by the progress we’ve made while continuing to deliver strong satisfaction levels across our referenceable customer base. This stability provides a solid foundation as we advance into the next phase of our growth strategy,” said Jeffrey Jagid, Chief Executive Officer of Atlantic International Corp.
Atlantic International Corp. (NASDAQ:ATLN) is a strategic staffing, outsourced services, and workforce solutions company that operates primarily through its subsidiary, Lyneer Investments LLC, to provide staffing in areas like light industrial, professional, and finance.
6. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
3-Year Sales Growth: 370.72%
Sales Growth Year over Year: 1255.21%
Stock Upside Potential: 174.74%
Number of Hedge Fund Holders: 15
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of the fastest-growing penny stocks to buy now. On November 18 at the Jefferies London Healthcare Conference 2025, Lexicon Pharmaceuticals (NASDAQ:LXRX) reiterated it is making significant progress in developing its pipeline.
For starters, it is preparing for the end-of-phase two meeting with the US Food and Drug Administration for pilavapadin, a candidate drug targeting neuropathic pain. Additionally, it is accelerating patient enrollment in the SONATA trial for hypertrophic cardiomyopathy (HCM). Lexicon is also resubmitting Zynquista for type 1 diabetes to the FDA in early 2026.
On November 10, at the American Heart Association Annual Scientific Sessions 2025, Lexicon delivered topline results for sotagliflozin, showing significant improvements in heart failure patients with preserved ejection fraction.
“Although sotagliflozin was approved more than two years ago for heart failure patients with or without diabetes, our study is the first to demonstrate important clinical benefits for patients with preserved ejection fraction without diabetes,” said Dr. Juan J Badimon at Mount Sinai Medical Center.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company that discovers, develops, and commercializes medicines for serious and chronic diseases. The company focuses on cardiometabolic (heart and metabolic health) and neuroscience (nervous system) conditions.
5. Immunitybio Inc. (NASDAQ:IBRX)
3-Year Sales Growth:150.86%
Sales Growth Year over Year: 1025.95%
Stock Upside Potential: 221.84%
Number of Hedge Fund Holders: 14
Immunitybio Inc. (NASDAQ:IBRX) is one of the fastest-growing penny stocks to buy now. On November 4, the company affirmed strong demand for Anktiva, used to treat bladder cancer, as it delivered impressive third-quarter results characterized by robust product sales.
The company delivered product revenue of $31.8 million, representing a 434% increase from the third quarter of last year. The year-over-year revenue increase came on the back of commercial traction for ANKTIVA in combination with BCG in BCG-unresponsive NMIBC with CIS. Consequently, the company’s revenue for the first nine months of the year is up 467% to $74.7 million.
“Unit sales grew nearly 6X year-to-date compared with full-year 2024, reflecting adoption both at leading research centers and in community urology clinics, including rural areas,” said Richard Adcock, President and CEO of ImmunityBio. “ANKTIVA’s total response rate continues to gain momentum with payors as it was recently added as the preferred drug in its indication by a large medication contracting organization covering ~80 million lives.
Amid robust product revenue growth, the net loss shrank to $67.3 million, compared to $85.7 million in the third quarter of last year. The lower net loss was driven by higher product revenue and lower related party interest expense.
Following better-than-expected third-quarter results, H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on the stock and an $8.00 price target.
Immunitybio Inc. (NASDAQ:IBRX) is a biotechnology company that develops immunotherapy and cell therapy products to treat cancers and infectious diseases. The company’s platform works to boost the natural immune system to fight disease, with a focus on durable, safe protection.
4. NextNRG Inc. (NASDAQ:NXXT)
3-Year Sales Growth: 56.58%
Sales Growth Year over Year: 146.01%
Stock Upside Potential: 253.36%
Number of Hedge Fund Holders: N/A
NextNRG Inc. (NASDAQ:NXXT) is one of the fastest-growing penny stocks to buy now. On November 17, NextNRG Inc. (NASDAQ:NXXT) delivered strong third-quarter results characterized by robust revenue growth, margin expansion, and continued traction in the energy infrastructure segment.
Third-quarter revenue was up 232% year over year to $22.9 million, driven by aggressive expansion into new markets and increased operational density around anchor customers. Gross profit totaled $2.4 million, as margins expanded to 11% from 8% in the second quarter. While the company posted a net loss of $14.9 million, it was due to non-cash stock-based compensation and growth-related investments that strengthen the company’s long-term operating capacity.
In a bid to accelerate growth, NextNRG remains focused on expanding its footprint into high-demand sectors. It’s also focused on driving efficiency and resiliency for customers across healthcare, commercial, and municipal markets. The company also continues to advance its AI-driven innovative microgrid projects.
“We are entering an exciting phase where our technology, infrastructure, and operational expertise converge. Our fully connected energy ecosystem continues to deliver measurable results, positioning NextNRG to lead the transition to intelligent, distributed power,” said Michael D. Farkas, Executive Chairman and CEO.
NextNRG Inc. (NASDAQ:NXXT) develops and integrates an energy ecosystem that combines mobile fueling, renewable energy, and on-demand services. It leverages artificial intelligence (AI) and machine learning (ML) to manage an integrated platform that includes solar energy, battery storage, wireless EV charging, and on-demand fuel delivery.
3. Geron Corporation (NASDAQ:GERN)
3-Year Sales Growth: 280.92%
Sales Growth Year over Year: 522.13%
Stock Upside Potential: 273.83%
Number of Hedge Fund Holders: 37
Geron Corporation (NASDAQ:GERN) is one of the fastest-growing penny stocks to buy now. On November 11 at the Stifel 2025 Healthcare Conference, it reiterated plans to overcome challenges as it seeks to enhance the commercialization of Rytelo, a prescription medication used to treat anemia.
The company plans to shift Rytelo’s use to earlier treatment lines. Part of the plan entails positioning the candidate drug for earlier use in the treatment setting, especially as a second-line therapy. Geron is to implement a surround-sound approach that will increase physician awareness and engagement. While the drug’s sales stagnated in 2025 at about $50 million, the company is optimistic of significant growth in 2026.
Amid the proposed sales plans for Rytelo, Needham analyst Gil Blum has reiterated a Buy rating and set a $4 price target. On the other hand, Leerink Partners reiterated an Outperform rating on the stock on November 5 but cut the price target to $2 from $3. Leerink reaffirmed an outperform rating, expecting the company to take the necessary steps to improve Rytelo’s performance, including expanding its field force.
Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on developing and commercializing medicines to treat blood cancers, specifically myeloid hematologic malignancies. Its main product, RYTELO (imetelstat), is an approved telomerase inhibitor for certain patients with lower-risk myelodysplastic syndromes, and the company is researching its use in other blood cancers.
2. Gevo, Inc. (NASDAQ:GEVO)
3-Year Sales Growth: 216.60%
Sales Growth Year over Year: 675.75%
Stock Upside Potential: 312.69%
Number of Hedge Fund Holders: 5
Gevo Inc. (NASDAQ:GEVO) is one of the fastest-growing penny stocks to buy now. On November 11, analyst Amit Dayal from H.C. Wainwright reiterated a Buy rating and a $14 price target on Gevo Inc. (NASDAQ:GEVO). The positive stance is in response to strong third-quarter results that demonstrated a robust revenue stream and a strategic focus on effective carbon monetization.
The leading developer of cost-effective, renewable hydrocarbon fuels and chemicals posted revenue of $43.71 million, exceeding consensus estimates of $37.03 million. While the company posted a net loss of $0.03 a share, it was better than the $0.04 per-share loss analysts expected. The company also achieved a second consecutive quarter of positive adjusted EBITDA, driven by strong performance at the Gevo North Dakota facility and renewable natural gas (“RNG”) facility.
Loss from operations decreased by $20.3 million compared to the same quarter last year, owing to improvements driven by increased revenues from Gevo North Dakota and lower production costs.
“We are generating positive Adjusted EBITDA, and we have plans to make it even stronger. Our profitability as a company doesn’t depend on deploying jet fuel. We do however remain committed to developing the jet fuel business, as we expect jet fuel sales to add significant Adjusted EBITDA to our business,” said Dr. Patrick Gruber, Gevo’s Chief Executive Officer
Gevo also inked a multi-year off-take agreement expected to generate $26 million in Carbon Dioxide Removal credit sales revenue over the next five years.
Gevo, Inc. (NASDAQ:GEVO) is a renewable chemicals and advanced biofuels company that converts renewable energy and bio-based feedstocks into low-carbon products, including sustainable aviation fuel, renewable gasoline, diesel, and chemicals.
1. Autolus Therapeutics plc. (NASDAQ:AUTL)
3-Year Sales Growth: 88.69%
Sales Growth Year over Year: 407.86%
Stock Upside Potential: 504.72%
Number of Hedge Fund Holders: 16
Autolus Therapeutics plc. (NASDAQ:AUTL) is one of the fastest-growing penny stocks to buy now. On November 18 at the Jefferies London Healthcare Conference 2025, CEO Christian Itin reiterated that Autolus Therapeutics PLC (NASDAQ:AUTL) is positioning itself to be a leader in CAR-T therapies. The push comes as the company generated $21.1 million in product revenue in the third quarter, attributed to its CAR-T therapy, AUCATZYL.
In a bid to bolster CAR-T therapy revenues, Autolus plans to launch Ocatzel, its other flagship product for adult acute lymphoblastic leukemia (ALL), with a focus on expanding its market reach and exploring new target areas. The therapy is already available in more than 60 active centers, having generated $51 million in sales in the first nine months of the year.
Plans are underway to explore its potential use in Pediatric ALL and autoimmune diseases to enhance its market target. In addition, it has set its sights on increasing physician adoption and patient awareness to grow market share over the next two years. The company has already established an end-to-end infrastructure to enhance production and supply in the UK and the US.
Autolus Therapeutics plc. (NASDAQ:AUTL) develops and manufactures programmed T cell therapies, primarily CAR T-cell therapies, for the treatment of cancer and autoimmune diseases. It focuses on creating next-generation immunotherapies that are precisely targeted, controlled, and highly active.
While we acknowledge the potential of Autolus Therapeutics plc. (NASDAQ:AUTL) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUTL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: Top 10 Stocks Offering High Upside Potential in Data Centers and 10 Best Breakout Stocks to Invest In.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
